KLRK1 and neoplasm: Researchers developed a new type of Bispecific T cell engagers CAR-T (BiTEs CAR-T) cells, which can target MSLN and secrete NKG2D-BiTEs to bind NKG2D ligands. The results showed that these BiTEs CAR-T cells exhibited excellent performance in killing tumor cells, activating T cells, and producing cytokines. Moreover, they demonstrated a remarkable anti-tumor effect and good safety profile in animal models.